Sunday, June 14, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 252 of 1,261
  1. US 11390921

    Determining WT-1 specific T cells and WT-1 specific T cell receptors (TCRs)

    Adaptive Biotechnologies Corporation · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  2. US 11390884

    Optimized CRISPR/cas9 systems and methods for gene editing in stem cells

    Editas Medicine, Inc. · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  3. US 11390848

    Materials and methods for modifying the activity of T cells

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  4. US 11390683

    Anti-mesothelin polypeptides and proteins

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  5. US 11390667

    Compositions and methods for the treatment of neuromyelitis optica

    The Regents of the University of California · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  6. US 11390631

    Benzodiazepine derivatives as RSV inhibitors

    Enanta Pharmaceuticals, Inc. · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  7. US 11389663

    Laser assisted wound healing protocol and system

    BIOREGENTECH, INC. · Granted Jul 19, 2022 · Expires Jul 14, 2042

    granted
  8. CA 3207179

    METHODES DE TRAITEMENT DE LA MALADIE DE CROHN ET DE LA COLITE ULCEREUSE

    ABBVIE INC [US] · Granted Jul 14, 2022 · Expires Jul 9, 2042

    granted
  9. US 11384139

    Antibody targeting cell surface deposited complement protein C3d and use thereof

    THE UNITED STATES OF AMERICA, represented by the Secretary, Department of Health and Human Services · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  10. US 11382890

    Prevention of rosacea inflammation

    The Regents of the University of California · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  11. US 11384154

    Targeted chimeric proteins and uses thereof

    Orionis Biosciences, Inc · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  12. US 11384355

    Compositions and methods for inhibiting gene expression of alpha-1 AntiTrypsin

    Arrowhead Pharmaceuticals, Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  13. US 11385233

    Methods of depleting malignant T-cells

    AUTOLUS LIMITED · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  14. US 11384153

    Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  15. US 11384335

    Genetically-modified immune cells comprising a microRNA-adapted shRNA (shRNAmiR)

    Precision BioSciences, Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  16. US 11382922

    Aqueous oral pharmaceutical suspension compositions

    ReveraGen BioPharma, Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  17. US 11382981

    Exon skipping oligomer conjugates for muscular dystrophy

    Sarepta Therapeutics, Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  18. US 11384350

    Cytotoxic molecules responsive to intracellular ligands for selective T cell mediated killing

    The Regents of the University of California · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  19. US 11384098

    Pyrrolobenzodiazepine-antibody conjugates

    ADC THERAPEUTICS SA · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  20. US 11384076

    Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) FLT3 inhibitors

    Universität Regensburg · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  21. US 11384065

    Heterocyclic compound as CSF-1R inhibitor and use thereof

    Medshine Discovery Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  22. US 11384055

    Glycolate oxidase inhibitors for the treatment of disease

    BIOMARIN PHARMACEUTICAL INC. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  23. US 11384062

    Deuterated (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide

    CombiPhos Catalysts, Inc. · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted
  24. US 11382989

    Engineered microbial population

    The Board of Regents of the University of Texas System · Granted Jul 12, 2022 · Expires Jul 7, 2042

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.